NEXTBio Capital Management LP bought a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund bought 1,298,701 shares of the company’s stock, valued at approximately $6,039,000. Inventiva makes up about 3.5% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 11th biggest position.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Creative Planning acquired a new stake in Inventiva in the 2nd quarter valued at approximately $32,000. NewEdge Advisors LLC acquired a new stake in Inventiva in the 3rd quarter valued at approximately $116,000. Cerity Partners LLC acquired a new stake in Inventiva in the 4th quarter valued at approximately $93,000. Commonwealth Equity Services LLC raised its position in Inventiva by 19.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after buying an additional 12,704 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in Inventiva in the 3rd quarter valued at approximately $649,000. Institutional investors and hedge funds own 19.06% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on IVA. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Truist Financial began coverage on Inventiva in a research report on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price on the stock. Finally, Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $16.56.
Inventiva Stock Up 1.3%
NASDAQ:IVA opened at $3.85 on Friday. Inventiva S.A. Sponsored ADR has a twelve month low of $2.85 and a twelve month high of $7.98. The stock’s 50 day moving average price is $5.07 and its two-hundred day moving average price is $5.39.
Inventiva (NASDAQ:IVA – Get Free Report) last posted its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $0.01 million during the quarter. Sell-side analysts anticipate that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current fiscal year.
About Inventiva
Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.
The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.
Featured Articles
- Five stocks we like better than Inventiva
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Want to see what other hedge funds are holding IVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Free Report).
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
